💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Glyburide

CHEMBL472 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
494.0 g/mol
LogP
4.8
Phase
4

A sulfonylurea medication that treats type 2 diabetes and gestational diabetes by stimulating the pancreas to release more insulin and making body cells more responsive to insulin's effects. It also has cardiovascular applications under investigation, including potential benefits in atrial fibrillation management. Blood sugar monitoring is essential as hypoglycemia is the most common serious side effect.

الوزن الجزيئي

494,0000 g/mol

LogP

4,80

TPSA

122,00 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Cardiovascular Disease Pain Management Epilepsy Migraine Multiple Sclerosis Non-Alcoholic Fatty Liver Disease Stroke Obesity Type 2 Diabetes Hypertension Chronic Pain

آلية العمل

Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)

                

                

                

                    
                    

                        
Molecular Formula

                        
C23H28ClN3O5S

                    

                    
                    

                        
HBD / HBA

                        
3 / 5

                    

                    
                    

                        
الروابط القابلة للدوران

                        
8

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
33

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
A sulfonylurea medication that treats type 2 diabetes and gestational diabetes by stimulating the pancreas to release more insulin and making body cells more responsive to insulin's effects. It also has cardiovascular applications under investigation, including potential benefits in atrial fibrillation management. Blood sugar monitoring is essential as hypoglycemia is the most common serious side effect.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Glyburide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL472.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3488.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.